WILLS EYE IS HIRING – CLICK HERE TO APPLY TODAY!

Retina Clinical Trials – Wet Macular Degeneration

RETINA_Research Clinical Trials Header slide
Age Related Macular Degeneration
RETINA RESEARCH
Improving patient care now and for future generations.
Age Related Macular Degeneration

Macular Degeneration Clinical Trials

Neovascular (Wet) Age-Related Macular Degeneration

Longer-Acting Pharmacologic Agents

Kodiak Sciences (DAZZLE)*
A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus Aflibercept in patients with neovascular (wet) age-related macular degeneration. (DAZZLE).
Learn more.

Graybug Vision  (ALTISSIMO)
A depot formulation of Sunitinib Malate (GB-102) compared to Aflibercept in subjects with neovascular (wet) age-related macular degeneration (ALTISSIMO).
Learn more.

Roche/Genentech (TENAYA)
A study to evaluate the efficacy and safety of Faricimab in participants with neovascular age-related macular degeneration (TENAYA).
Learn more.

*pending

Roche/Genentech (LUCERNE)
A study to evaluate the efficacy and safety of Faricimab in participants with neovascular (wet) age-related macular degeneration (LUCERNE).
Learn more.

Novartis (MERLIN)
Study of safety and efficacy of Brolucizumab 6 mg dosed rvery 4 weeks compared to Aflibercept 2 mg dosed every 4 weeks in patients with retinal fluid despite frequent anti-VEGF injections (MERLIN).
Learn more.

Chengdu Kanghong (PANDA)
Efficacy and safety trial of Conbercept intravitreal injection for neovascular (wet) age-related macular degeneration (PANDA-1).
Learn more.

For more information about
Retina Clinical Trials,

call 215-928-3444

Aerie
A study assessing AR-13503 implant alone and in combination with Aflibercept in subjects with nAMD or DME.
Learn more.

Port Delivery System (PDS)

Roche /Genentech (ARCHWAY)
A Phase III study to evaluate the port delivery system with Ranibizumab compared with monthly Ranibizumab injections in participants with neovascular (wet) age-related macular degeneration (Archway).
Learn more.

Roche /Genentech (PORTAL)
Extension study for the port delivery system with Ranibizumab (Portal).
Learn more.

Gene Therapy

Regenexbio
RGX-314 gene therapy for neovascular (wet) age-related macular degeneration trial. This viral vector is administered as a single dose via subretinal delivery during outpatient surgery.
Learn more.

Adverum Biotechnologies (OPTIC)
ADVM-022 intravitreal gene therapy for neovascular (wet) age-related macular degeneration (OPTIC). This viral vector is administered by a one-time intravitreal injection.
Learn more.


Dry Age-Related Macular Degeneration

Anti-Inflammation

Apellis OAKS
Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration.
Learn more. 

Genentech (GALLEGO)
A study assessing the safety, tolerability, and efficacy of RO7171009 in participants with geographic atrophy secondary to dry age-related macular degeneration (GALLEGO).
Learn more.

Ophthotech
Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration.
Learn more.

Boehringer Ingelheim Pharmaceuticals
Safety, tolerability, and pharmacokinetics of single doses BI 425809.
Learn more.

University of Virginia TOGA
Clinical study to evaluate treatment with ORACEA® (oral doxycycline) for geographic atrophy (TOGA).
Learn more.

Cell Based

Astellas (AIRM)
A Phase 1b dose escalation evaluation of safety and tolerability and a Phase 2 proof of concept investigation of efficacy and safety of ASP7317 for atrophy secondary to dry age-related macular degeneration.
Learn more.

Lineage/Cellcure*
Safety and efficacy study of OpRegen for treatment of advanced dry age-related macular degeneration.
Learn more.

Genetic Screening

MedSpace (Gyroscope Therapeutics)
To evaluate the natural progression of dry age-related macular degeneration.
Learn more.

*pending

Gemini Therapeutics
A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central geographic atrophy (GA) who are carriers of high-risk genetic complement variants associated with dry age-related macular degeneration (AMD).